Literature DB >> 28342823

Evidence that increased Kcnj6 gene dose is necessary for deficits in behavior and dentate gyrus synaptic plasticity in the Ts65Dn mouse model of Down syndrome.

Alexander M Kleschevnikov1, Jessica Yu2, Jeesun Kim2, Larisa V Lysenko3, Zheng Zeng2, Y Eugene Yu4, William C Mobley2.   

Abstract

Down syndrome (DS), trisomy 21, is caused by increased dose of genes present on human chromosome 21 (HSA21). The gene-dose hypothesis argues that a change in the dose of individual genes or regulatory sequences on HSA21 is necessary for creating DS-related phenotypes, including cognitive impairment. We focused on a possible role for Kcnj6, the gene encoding Kir3.2 (Girk2) subunits of a G-protein-coupled inwardly-rectifying potassium channel. This gene resides on a segment of mouse Chromosome 16 that is present in one extra copy in the genome of the Ts65Dn mouse, a well-studied genetic model of DS. Kir3.2 subunit-containing potassium channels serve as effectors for a number of postsynaptic metabotropic receptors including GABAB receptors. Several studies raise the possibility that increased Kcnj6 dose contributes to synaptic and cognitive abnormalities in DS. To assess directly a role for Kcnj6 gene dose in cognitive deficits in DS, we produced Ts65Dn mice that harbor only 2 copies of Kcnj6 (Ts65Dn:Kcnj6++- mice). The reduction in Kcnj6 gene dose restored to normal the hippocampal level of Kir3.2. Long-term memory, examined in the novel object recognition test with the retention period of 24h, was improved to the level observed in the normosomic littermate control mice (2N:Kcnj6++). Significantly, both short-term and long-term potentiation (STP and LTP) was improved to control levels in the dentate gyrus (DG) of the Ts65Dn:Kcnj6++- mouse. In view of the ability of fluoxetine to suppress Kir3.2 channels, we asked if fluoxetine-treated DG slices of Ts65Dn:Kcnj6+++ mice would rescue synaptic plasticity. Fluoxetine increased STP and LTP to control levels. These results are evidence that increased Kcnj6 gene dose is necessary for synaptic and cognitive dysfunction in the Ts65Dn mouse model of DS. Strategies aimed at pharmacologically reducing channel function should be explored for enhancing cognition in DS.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Cognition; Down syndrome critical region; Fluoxetine; Genotype-phenotype relationship; Kcnj6; Kir3.2; Learning; Locomotor activity; Long-term potentiation; Mouse models; Novel object recognition; Synaptic plasticity; Ts65Dn; Y-maze

Mesh:

Substances:

Year:  2017        PMID: 28342823      PMCID: PMC5446050          DOI: 10.1016/j.nbd.2017.03.009

Source DB:  PubMed          Journal:  Neurobiol Dis        ISSN: 0969-9961            Impact factor:   5.996


  103 in total

Review 1.  Clinical Assessment of Cognitive Decline in Adults with Down Syndrome.

Authors:  Marwan Sabbagh; Jamie Edgin
Journal:  Curr Alzheimer Res       Date:  2016       Impact factor: 3.498

2.  Working memory and Down syndrome.

Authors:  A Baddeley; C Jarrold
Journal:  J Intellect Disabil Res       Date:  2007-12

3.  Early pharmacotherapy restores neurogenesis and cognitive performance in the Ts65Dn mouse model for Down syndrome.

Authors:  Patrizia Bianchi; Elisabetta Ciani; Sandra Guidi; Stefania Trazzi; Daniela Felice; Gabriele Grossi; Mercedes Fernandez; Alessandro Giuliani; Laura Calzà; Renata Bartesaghi
Journal:  J Neurosci       Date:  2010-06-30       Impact factor: 6.167

4.  A potassium channel mutation in weaver mice implicates membrane excitability in granule cell differentiation.

Authors:  N Patil; D R Cox; D Bhat; M Faham; R M Myers; A S Peterson
Journal:  Nat Genet       Date:  1995-10       Impact factor: 38.330

5.  Genetic dissection of the Down syndrome critical region.

Authors:  Xiaoling Jiang; Chunhong Liu; Tao Yu; Li Zhang; Kai Meng; Zhuo Xing; Pavel V Belichenko; Alexander M Kleschevnikov; Annie Pao; Jennifer Peresie; Sarah Wie; William C Mobley; Y Eugene Yu
Journal:  Hum Mol Genet       Date:  2015-09-15       Impact factor: 6.150

6.  GIRK2 deficient mice. Evidence for hyperactivity and reduced anxiety.

Authors:  Y A Blednov; M Stoffel; S R Chang; R A Harris
Journal:  Physiol Behav       Date:  2001 Sep 1-15

7.  G protein-coupled inwardly rectifying K+ channels (GIRKs) mediate postsynaptic but not presynaptic transmitter actions in hippocampal neurons.

Authors:  C Lüscher; L Y Jan; M Stoffel; R C Malenka; R A Nicoll
Journal:  Neuron       Date:  1997-09       Impact factor: 17.173

Review 8.  Beta-amyloid, oxidative stress and down syndrome.

Authors:  Ira T Lott; Elizabeth Head; Eric Doran; Jorge Busciglio
Journal:  Curr Alzheimer Res       Date:  2006-12       Impact factor: 3.498

Review 9.  Mouse models of Down syndrome as a tool to unravel the causes of mental disabilities.

Authors:  Noemí Rueda; Jesús Flórez; Carmen Martínez-Cué
Journal:  Neural Plast       Date:  2012-05-22       Impact factor: 3.599

10.  Monoacylglycerol lipase inhibitor JZL184 improves behavior and neural properties in Ts65Dn mice, a model of down syndrome.

Authors:  Larisa V Lysenko; Jeesun Kim; Cassandra Henry; Anna Tyrtyshnaia; Rebecca A Kohnz; Francisco Madamba; Gabriel M Simon; Natalia E Kleschevnikova; Daniel K Nomura; R Alan B Ezekowitz; Alexander M Kleschevnikov
Journal:  PLoS One       Date:  2014-12-04       Impact factor: 3.240

View more
  10 in total

Review 1.  Genetic and epigenetic pathways in Down syndrome: Insights to the brain and immune system from humans and mouse models.

Authors:  Y Eugene Yu; Zhuo Xing; Catherine Do; Annie Pao; Eun Joon Lee; Sharon Krinsky-McHale; Wayne Silverman; Nicole Schupf; Benjamin Tycko
Journal:  Prog Brain Res       Date:  2019-10-24       Impact factor: 2.453

Review 2.  Neuronal G protein-gated K+ channels.

Authors:  Haichang Luo; Ezequiel Marron Fernandez de Velasco; Kevin Wickman
Journal:  Am J Physiol Cell Physiol       Date:  2022-06-15       Impact factor: 5.282

3.  Impact of increased APP gene dose in Down syndrome and the Dp16 mouse model.

Authors:  Mariko Sawa; Cassia Overk; Ann Becker; Dominique Derse; Ricardo Albay; Kim Weldy; Ahmad Salehi; Thomas G Beach; Eric Doran; Elizabeth Head; Y Eugene Yu; William C Mobley
Journal:  Alzheimers Dement       Date:  2021-11-10       Impact factor: 16.655

Review 4.  GABAB Receptors and Cognitive Processing in Health and Disease.

Authors:  Styliani Vlachou
Journal:  Curr Top Behav Neurosci       Date:  2022

Review 5.  Targeting trisomic treatments: optimizing Dyrk1a inhibition to improve Down syndrome deficits.

Authors:  Megan Stringer; Charles R Goodlett; Randall J Roper
Journal:  Mol Genet Genomic Med       Date:  2017-09-20       Impact factor: 2.183

6.  Restoring neuronal chloride homeostasis with anti-NKCC1 gene therapy rescues cognitive deficits in a mouse model of Down syndrome.

Authors:  Martina Parrini; Shovan Naskar; Micol Alberti; Ilaria Colombi; Giovanni Morelli; Anna Rocchi; Marina Nanni; Federica Piccardi; Severine Charles; Giuseppe Ronzitti; Federico Mingozzi; Andrea Contestabile; Laura Cancedda
Journal:  Mol Ther       Date:  2021-05-29       Impact factor: 12.910

7.  A Method for Bridging Population-Specific Genotypes to Detect Gene Modules Associated with Alzheimer's Disease.

Authors:  Yulin Dai; Peilin Jia; Zhongming Zhao; Assaf Gottlieb
Journal:  Cells       Date:  2022-07-16       Impact factor: 7.666

Review 8.  Enhanced GIRK2 channel signaling in Down syndrome: A feasible role in the development of abnormal nascent neural circuits.

Authors:  Alexander M Kleschevnikov
Journal:  Front Genet       Date:  2022-09-12       Impact factor: 4.772

9.  Alcohol reverses the effects of KCNJ6 (GIRK2) noncoding variants on excitability of human glutamatergic neurons.

Authors:  Dina Popova; Isabel Gameiro-Ros; Mark M Youssef; Petronio Zalamea; Ayeshia D Morris; Iya Prytkova; Azadeh Jadali; Kelvin Y Kwan; Chella Kamarajan; Jessica E Salvatore; Xiaoling Xuei; David B Chorlian; Bernice Porjesz; Samuel Kuperman; Danielle M Dick; Alison Goate; Howard J Edenberg; Jay A Tischfield; Zhiping P Pang; Paul A Slesinger; Ronald P Hart
Journal:  Mol Psychiatry       Date:  2022-10-07       Impact factor: 13.437

10.  Targeting increased levels of APP in Down syndrome: Posiphen-mediated reductions in APP and its products reverse endosomal phenotypes in the Ts65Dn mouse model.

Authors:  Xu-Qiao Chen; Ahmad Salehi; Matthew L Pearn; Cassia Overk; Phuong D Nguyen; Alexander M Kleschevnikov; Maria Maccecchini; William C Mobley
Journal:  Alzheimers Dement       Date:  2020-09-25       Impact factor: 21.566

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.